Table 1.
Characteristics of plasma donation and alloimmunized plasma donors.
Fig 1.
Fractionation scheme of plasma for the preparation of anti-human platelet antigen (HPA)-1a immunoglobulin G.
Fig 2.
SDS-PAGE profile of anti-human platelet antigen (HPA)-1a fractions generated throughout the purification process.
A: Non-reducing conditions; B: reducing conditions. 1: cryoprecipitate-poor plasma; 2: caprylic acid supernatant; 3: S HyperCel breakthrough; 4: S HyperCel eluate; 5: HyperCel STAR-AX breakthrough; 6: HyperCel STAR-AX eluate; 7: after nanofiltration; 8: after concentration; 9: final fraction after dialysis. The left lane shows molecular weight markers. Staining was with Coomassie blue. FL-IgG, intact whole IgG; HC-IgG, heavy-chain IgG; LC-IgG, light-chain IgG.
Fig 3.
Densitometric analysis of the zone electrophoresis of fractions generated throughout the purification process showing the relative proportions of proteins migrating as gamma, beta, alpha-2, and alpha-1 proteins, and albumin.
Fig 4.
Contents of total proteins, immunoglobulin G (IgG), IgA, IgM, albumin, and complement 3 (C3) and C4 fractions throughout the purification process.
Table 2.
Thrombin generation assay using RC high comparing cryoprecipitate-poor plasma and purified anti-HPA-1a IgG.
Mean +/- SD (mini-maxi). AUC: area under the curve.
Table 3.
Semi-quantitative determination of platelet antigens by PAK-12 assay.
Fig 5.
Quantitative monoclonal antibody immobilization of platelet antigen (MAIPA) assay of anti-HPA-1a IgG at different step of the purification process.
Fig 6.
Removal of the hepatitis C virus (HCV) during nanofiltration as determined using luciferase reporter measurements (log10 RLU).
N = 3. Mean ± SEM. The dashed line indicates the background level of luciferase activity.